Medical devices, healthcare technology and the business of care
510(k) clearance · K262392

APRO 35 Swift Catheter

Alembic, LLC · Decision date Aug 12, 2026

FDA DECISIONK262392

What did the FDA decide?

FDA records K262392 as a 510(k) premarket notification, with a decision dated Aug 12, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Cardiovascular
Decision date
Aug 12, 2026

FDA source record

Regulatory record facts

Identifier
K262392
Regulatory pathway
510(k) premarket notification
Applicant
Alembic, LLC
Product code
DQY
Decision code
SESE
Decision date
Aug 12, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Catheter, Percutaneous.

Applicant
Alembic, LLC
Product code
DQY
FDA device class
2

FDA decision timeline

  1. K262392 received

    Application receipt date recorded by FDA.

  2. K262392 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code DQY

Product / regulatory recordCompanyPathwayDecision dateSource
Vantis Vascular, Inc.510(k) clearanceSep 18, 2026FDA
NHanceITK260559
IMDS Operation B.V.510(k) clearanceAug 14, 2026FDA
CenterPoint Systems, LLC510(k) clearanceJul 29, 2026FDA
CenterPoint Systems, LLC510(k) clearanceJul 29, 2026FDA
Abbott510(k) clearanceJul 2, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Alembic, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Mountain View, CA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records